Prophylactic Use of Milrinone After Congenital Heart Surgery in Infants

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This randomized, multi‐center, double‐blinded, placebo‐controlled study is designed to evaluate the efficacy and safety of milrinone compared with placebo in participants after corrective surgery for congenital heart disease. Participants will be randomized in a 1:1 ratio within 90 minutes after arriving in the intensive care unit (ICU), to receive either intravenous milrinone or placebo for 36 hours. Participants will be stratified according Vasoactive Inotrope Score after arriving in the ICU.
Epistemonikos ID: d72c0ab74ac1666f5459c3e18e23204ea5f8ff70
First added on: May 22, 2024